Transcriptional regulation of the c-Myc promoter by NFAT1 involves negative and positive NFAT-responsive elements

Cell Cycle

Volumn 11, Issue 5, 2012, Pages 1014-1028

  Mognol, Giuliana P ^a   De Araujo Souza, Patricia S ^a,b   Robbs, Bruno K ^a   Teixeira, Leonardo K ^a,c   Viola, João P B ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

c Myc; Gene expression; Gene promoter; NFAT; Transcription factor

Indexed keywords

CALCINEURIN; CALCIUM; MYC PROTEIN; PROTEIN P300; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL STRAIN HEK293; CELL TYPE; DNA RESPONSIVE ELEMENT; DOMINANT GENE; EMBRYO; GENE CONTROL; GENE DELETION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RECESSIVE GENE; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION; TRANSCRIPTION REGULATION;

EID: 84857957581     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.5.19518     Document Type: Article

References (66)

1. Wierstra I, Alves J. The c-myc promoter: still MysterY and challenge. Adv Cancer Res 2008; 99:113-333; PMID:18037408; http://dx.doi.org/10.1016/S0065- 230X(07)99004-1.
2. Evan GI, Christophorou M, Lawlor EA, Ringshausen I, Prescott J, Dansen T, et al. Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy. Cold Spring Harb Symp Quant Biol 2005; 70:263-73; PMID:16869762; http://dx.doi. org/10.1101/sqb.2005.70.054.
3. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 2006; 103:17834-9; PMID:17093053; http:// dx.doi.org/10.1073/ pnas.0604129103.
4. Levens D. How the c-myc promoter works and why it sometimes does not. J Natl Cancer Inst Monogr 2008:41-3; PMID:18648001; http://dx.doi. org/10.1093/jncimonographs/lgn004.
5. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16:318-30; PMID:16934487; http://dx.doi. org/10.1016/j.semcancer.2006.07.015.
6. Levens D. You Don't Muck with MYC. Genes Cancer 2010; 1:547-54; PMID:20882108; http://dx.doi. org/10.1177/1947601910377492.
7. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin and NFAT. Genes Dev 2003; 17:2205-32; PMID:12975316; http:// dx.doi.org/10.1101/gad.1102703.
8. Avni O, Lee D, Macian F, Szabo SJ, Glimcher LH, Rao AT. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 2002; 3:643-51; PMID:12055628.
9. Bert AG, Johnson BV, Baxter EW, Cockerill PN. A modular enhancer is differentially regulated by GATA and NFAT elements that direct different tissue-specific patterns of nucleosome positioning and inducible chromatin remodeling. Mol Cell Biol 2007; 27:2870-85; PMID:17283044; http://dx.doi.org/10. 1128/ MCB.02323-.
10. Johnson BV, Bert AG, Ryan GR, Condina A, Cockerill PN. Granulocyte-macrophage colony-stimulating factor enhancer activation requires cooperation between NFAT and AP-1 elements and is associated with extensive nucleosome reorganization. Mol Cell Biol 2004; 24:7914-30; PMID:15340054; http://dx.doi. org/10.1128/MCB.24.18.7914-30.2004.
11. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005; 5:472-84; PMID:15928679; http://dx.doi. org/10.1038/nri1632.
12. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15:707-47; PMID:9143705; http:// dx.doi.org/10.1146/annurev.immunol.15.1.707.
13. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR. Identification of a putative regulator of early T cell activation genes. Science 1988; 241:202-5; PMID:3260404; http://dx.doi.org/10.1126/science. 3260404.
14. Viola JP, Carvalho LD, Fonseca BP, Teixeira LK. NFAT transcription factors: from cell cycle to tumor development. Braz J Med Biol Res 2005; 38:335-44; PMID:15761612; http://dx.doi.org/10.1590/S0100-879X2005000300003.
15. Baksh S, Widlund HR, Frazer-Abel AA, Du J, Fosmire S, Fisher DE, et al. NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Mol Cell 2002; 10:1071-81; PMID:12453415; http://dx.doi. org/10.1016/S1097-2765(02)00701- 3.
16. Hernández GL, Volpert OV, Iñiguez MA, Lorenzo E, Martínez-Martínez S, Grau R, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001; 193:607-20; PMID:11238591; http://dx.doi. org/10.1084/jem.193.5.607.
17. Jauliac S, López-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 2002; 4:540-4; PMID:12080349; http://dx.doi. org/10.1038/ncb816.
18. 2+/calcineurin signaling pathway. EMBO J 2006; 25:3714-24; PMID:16874304; http://dx.doi. org/10.1038/sj.emboj.7601246.
19. Köenig A, Linhart T, Schlengemann K, Reutlinger K, Wegele J, Adler G, et al. NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology 2010; 138:1189-99; PMID:19900447; http://dx.doi. org/10.1053/j.gastro.2009.10.045.
20. Pham LV, Tamayo AT, Li C, Bueso-Ramos C, Ford RJ. An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas. Blood 2010; 116:3899-906; PMID:20664054; http://dx.doi. org/10.1182/blood-2009-12-257378.
21. Singh G, Singh SK, König A, Reutlinger K, Nye MD, Adhikary T, et al. Sequential activation of NFAT and c-Myc transcription factors mediates the TGFbeta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 2010; 285:27241- 50; PMID:20516082; http://dx.doi.org/10.1074/jbc. M110.100438.
22. Furue M, Katz SI, Kawakami Y, Kawakami T. Coordinate expression of src family protooncogenes in T cell activation and its modulation by cyclosporine. J Immunol 1990; 144:736-9; PMID:2104905.
23. Golay J, Cusmano G, Introna M. Independent regulation of c-myc, B-myb and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes. J Immunol 1992; 149:300-8; PMID:1376749.
24. Nardone J, Lee DU, Ansel KM, Rao A. Bioinformatics for the 'bench biologist': how to find regulatory regions in genomic DNA. Nat Immunol 2004; 5:768-74; PMID:15282556; http://dx.doi.org/10.1038/ni0804-768.
25. Lee TI, Young RA. Transcription of eukaryotic protein-coding genes. Annu Rev Genet 2000; 34:77-137; PMID:11092823; http://dx.doi.org/10.1146/annurev. genet.34.1.77.
26. Kaminuma O, Kitamura F, Kitamura N, Hiroi T, Miyoshi H, Miyawaki A, et al. Differential contribution of NFATc2 and NFATc1 to TNFalpha gene expression in T cells. J Immunol 2008; 180:319-26; PMID:18097033.
27. Carvalho LD, Teixeira LK, Carrossini N, Caldeira AT, Ansel KM, Rao A, et al. The NFAT1 transcription factor is a repressor of cyclin A2 gene expression. Cell Cycle 2007; 6:1789-95; PMID:17637565; http:// dx.doi.org/10.4161/cc.6.14. 4473.
28. Youn HD, Chatila TA, Liu JO. Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO J 2000; 19:4323-31; PMID:10944115; http://dx.doi.org/10.1093/ emboj/19.16.4323.
29. Santini MP, Talora C, Seki T, Bolgan L, Dotto GP. Cross talk among calcineurin, Sp1/Sp3 and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA 2001; 98:9575-80; PMID:11493684; http://dx.doi. org/10.1073/pnas.161299698.
30. Liu J, Kouzine F, Nie Z, Chung HJ, Elisha-Feil Z, Weber A, et al. The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J 2006; 25:2119-30; PMID:16628215; http://dx.doi.org/10.1038/ sj.emboj.7601101.
31. Nagl NG Jr, Wang X, Patsialou A, Van Scoy M, Moran E. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell cycle control. EMBO J 2007; 26:752-63; PMID:17255939; http:// dx.doi.org/10.1038/sj. emboj.7601541.
32. Cockerill PN. NFAT is well placed to direct both enhancer looping and domain-wide models of enhancer function. Sci Signal 2008; 1:15; PMID:18385038; http://dx.doi.org/10.1126/stke.113pe15.
33. García-Rodríguez C, Rao A. Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP). J Exp Med 1998; 187:2031-6; PMID:9625762; http:// dx.doi.org/10.1084/jem.187.12.2031.
34. Liu C, Lu J, Tan J, Li L, Huang B. Human interleukin-5 expression is synergistically regulated by histone acetyltransferase CBP/p300 and transcription factors C/EBP, NF-AT and AP-1. Cytokine 2004; 27:93-100; PMID:15271374; http://dx.doi.org/10.1016/j. cyto.2004.02.003.
35. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001; 114:2363-73; PMID:11559745.
36. Avots A, Buttmann M, Chuvpilo S, Escher C, Smola U, Bannister AJ, et al. CBP/p300 integrates Raf/ Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation. Immunity 1999; 10:515-24; PMID:10367897; http://dx.doi. org/10.1016/S1074-7613(00)80051-5.
37. Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene 2008; 27:5717- 28; PMID:18542060; http://dx.doi.org/10. 1038/ onc.2008.181.
38. 1 exit in cells conditionally overexpressing p300 that is not dependent on its histone acetyltransferase activity. Proc Natl Acad Sci USA 2003; 100:9524-9; PMID:12883011; http://dx.doi.org/10.1073/ pnas.1633700100.
39. Robbs BK, Cruz AL, Werneck MB, Mognol GP, Viola JP. Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol Cell Biol 2008; 28:7168-81; PMID:18809576; http://dx.doi. org/10.1128/MCB.00256-08.
40. Remmers EF, Yang JQ, Marcu KB. A negative transcriptional control element located upstream of the murine c-myc gene. EMBO J 1986; 5:899-904; PMID:3013622.
41. Dudley JP, Mertz JA, Rajan L, Lozano M, Broussard DR. What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas. Leukemia 2002; 16:1086-98; PMID:12040439; http://dx.doi. org/10.1038/sj.leu.2402451.
42. Nielsen AA, Sørensen AB, Schmidt J, Pedersen FS. Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns and frequent error-prone gap repair. J Virol 2005; 79:67-78; PMID:15596802; http://dx.doi.org/10.1128/JVI.79.1.67-78.2005.
43. Gombert WM, Farris SD, Rubio ED, Morey-Rosler KM, Schubach WH, Krumm A. The c-myc insulator element and matrix attachment regions define the c-myc chromosomal domain. Mol Cell Biol 2003; 23:9338-48; PMID:14645543; http://dx.doi. org/10.1128/MCB.23.24.9338-48.2003.
44. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23:4225-31; PMID:15156177; http://dx.doi.org/10.1038/sj.onc.1207118.
45. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factoralpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996; 16:459-67; PMID:8552071.
46. Iñiguez MA, Martinez-Martinez S, Punzón C, Redondo JM, Fresno M. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 2000; 275:23627-35; PMID:10816557; http://dx.doi.org/ 10.1074/jbc.M001381200.
47. Duque J, Fresno M, Iñiguez MA. Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2. J Biol Chem 2005; 280:8686- 93; PMID:15632146; http://dx.doi.org/10.1074/jbc. M413076200.
48. Filippova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodwin G, et al. An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 1996; 16:2802-13; PMID:8649389.
49. Albert T, Wells J, Funk JO, Pullner A, Raschke EE, Stelzer G, et al. The chromatin structure of the dual c-myc promoter P1/P2 is regulated by separate elements. J Biol Chem 2001; 276:20482-90; PMID:11279041; http://dx.doi.org/10. 1074/jbc. M100265200.
50. Kumar S, Leffak M. DNA topology of the ordered chromatin domain 5′ to the human c-myc gene. Nucleic Acids Res 1989; 17:2819-33; PMID:2717410; http://dx.doi.org/10.1093/nar/17.7.2819.
51. Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 2006; 16:313-7; PMID:16935001; http://dx.doi.org/10.1016/j.semcancer. 2006.07.012.
52. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA 2007; 104:13028- 33; PMID:17664422; http://dx.doi.org/10.1073/ pnas.0701953104.
53. Marafioti T, Pozzobon M, Hansmann ML, Ventura R, Pileri SA, Roberton H, et al. The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. Br J Haematol 2005; 128:333-42; PMID:15667535; http://dx.doi.org/10.1111/j.1365- 2141.2004.05313.x.
54. Medyouf H, Ghysdael J. The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle 2008; 7:297- 303; PMID:18235236; http://dx.doi.org/10.4161/ cc.7.3.5357.
55. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005; 20:539-50; PMID:16307918; http:// dx.doi.org/10.1016/j. molcel.2005.10.033.
56. Yiu GK, Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem 2006; 281:12210-7; PMID:16505480; http://dx.doi.org/10.1074/jbc.M600184200.
57. 2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in human mammary epithelial cells. Mol Cell Biol 2006; 26:6024-36; PMID:16880514; http://dx.doi.org/10.1128/ MCB.02354-05.
58. Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, et al. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res 2006; 66:11565-70; PMID:17178846; http:// dx.doi.org/10.1158/0008-5472.CAN-06-2540.
59. Han Y, San-Marina S, Liu J, Minden MD. Transcriptional activation of c-myc proto-oncogene by WT1 protein. Oncogene 2004; 23:6933- 41; PMID:15286719; http://dx.doi.org/10.1038/ sj.onc.1207609.
60. Dydensborg AB, Teller IC, Groulx JF, Basora N, Paré F, Herring E, et al. Integrin alpha6Bbeta4 inhibits colon cancer cell proliferation and c-Myc activity. BMC Cancer 2009; 9:223; PMID:19586553; http://dx.doi. org/10.1186/1471-2407-9-223.
61. Xanthoudakis S, Viola JP, Shaw KT, Luo C, Wallace JD, Bozza PT, et al. An enhanced immune response in mice lacking the transcription factor NFAT1. Science 1996; 272:892-5; PMID:8629027; http://dx.doi. org/10.1126/science.272. 5263.892.
62. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509-12; PMID:9727977; http://dx.doi.org/10.1126/science. 281.5382.1509.
63. Chen CR, Kang Y, Massagué J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 2001; 98:992-9; PMID:11158583; http://dx.doi.org/10.1073/ pnas.98.3.992.
64. + T cells depends on NFAT1 transcription factor and regulates Th differentiation. J Immunol 2005; 175:5931-9; PMID:16237086.
65. Jain J, Burgeon E, Badalian TM, Hogan PG, Rao A. A similar DNA binding motif in NFAT family proteins and the Rel homology region. J Biol Chem 1995; 270:4138-45; PMID:7876165; http://dx.doi. org/10.1074/jbc.270.8.4138.
66. Jain J, McCaffrey PG, Valge-Archer VE, Rao A. Nuclear factor of activated T cells contains Fos and Jun. Nature 1992; 356:801-4; PMID:1533441; http:// dx.doi.org/10.1038/356801a0.